Latitude Pharmaceuticals Inc. Develops a Stable Liquid Glucagon Formulation

SAN DIEGO--(BUSINESS WIRE)--LATITUDE Pharmaceuticals, Inc. (LPI) announced today that its scientists have developed the first ever, ready-to-inject, stable liquid glucagon formulation (Nano-G). A glucagon formulation with these properties had been a highly sought after Holy Grail of drug developers for decades.

MORE ON THIS TOPIC